| Extension Study of ABP-671 in Participants With Gout (NCT06276556) | Atom Therapeutics Co., Ltd | 2024-04-22 |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors (NCT06384807) | Biohaven Therapeutics Ltd. | 2024-04-22 |
| Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances (NCT05110742) | M.D. Anderson Cancer Center | 2024-04-22 |
| A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer (NCT06398405) | Shandong Cancer Hospital and Institute | 2024-04-22 |
| Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT (NCT06349317) | Yongyi Zeng | 2024-04-22 |
| Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy (NCT06096870) | National Cancer Institute (NCI) | 2024-04-22 |
| Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia (NCT06333262) | Inhye Ahn | 2024-04-22 |
| A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (NCT05980806) | Karyopharm Therapeutics Inc | 2024-04-22 |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer (NCT06385080) | Janssen Research & Development, LLC | 2024-04-22 |
| Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma (NCT06364826) | Zhejiang Cancer Hospital | 2024-04-22 |
| Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia (NCT06490627) | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 2024-04-22 |
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia (NCT06603142) | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 2024-04-22 |
| Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC (NCT06288373) | Tongji Hospital | 2024-04-22 |
| A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients (NCT06732960) | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. | 2024-04-21 |
| Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients (NCT06249152) | Qlaris Bio, Inc. | 2024-04-21 |
| To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NCT06194448) | AstraZeneca | 2024-04-21 |
| CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL (NCT06064903) | Bambino Gesù Hospital and Research Institute | 2024-04-21 |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). (NCT06078306) | The First Affiliated Hospital of Soochow University | 2024-04-20 |
| HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer (NCT06383078) | The First Affiliated Hospital with Nanjing Medical University | 2024-04-20 |
| Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression (NCT06269211) | Ruijin Hospital | 2024-04-20 |
| Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC (NCT06366945) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2024-04-20 |
| Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (NCT07035054) | Jiangsu Province Centers for Disease Control and Prevention | 2024-04-20 |
| Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (NCT06678620) | Reinovax Biologics Co., LTD | 2024-04-20 |
| Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies (NCT07584889) | Shenzhen University General Hospital | 2024-04-20 |
| Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus (NCT06261021) | Innovaderm Research Inc. | 2024-04-19 |
| Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin (NCT06490484) | Haisco Pharmaceutical Group Co., Ltd. | 2024-04-19 |
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors (NCT05988918) | University of Michigan Rogel Cancer Center | 2024-04-19 |
| Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug (NCT06391736) | GeneCradle Inc | 2024-04-19 |
| Cancer Related Major Depression Treated With a Single Dose of Psilocybin (NCT06319378) | Section for Affective Disorders; Northern Stockholm Psychiatry | 2024-04-19 |
| Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas (NCT06350318) | H. Lee Moffitt Cancer Center and Research Institute | 2024-04-19 |
| Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial (NCT06356597) | Jing-yuan Fang, MD, Ph. D | 2024-04-19 |
| Sacituzumab Govitecan in Metastatic Colorectal Cancer (NCT06243393) | University Hospital Heidelberg | 2024-04-19 |
| Immunotherapy of the Recent-onset Type 1 Diabetes in Adolescents With Repeated Courses of Rituximab (NCT07041268) | Pirogov Russian National Research Medical University | 2024-04-19 |
| Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2) (NCT06167291) | M.D. Anderson Cancer Center | 2024-04-19 |
| A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (NCT06295809) | Merck Sharp & Dohme LLC | 2024-04-18 |
| EMBRACE: Exercising Together (NCT06049355) | OHSU Knight Cancer Institute | 2024-04-18 |
| A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction (NCT06195930) | Bayer | 2024-04-18 |
| Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum (NCT05325099) | National Taiwan University Hospital | 2024-04-18 |
| Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors (NCT06293651) | Dong-A ST Co., Ltd. | 2024-04-18 |
| Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study (NCT06345560) | Chulalongkorn University | 2024-04-18 |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC (NCT06217757) | Sichuan University | 2024-04-18 |
| Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy (NCT06164587) | Inflammasome Therapeutics | 2024-04-18 |
| A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults (NCT06382311) | GlaxoSmithKline | 2024-04-18 |
| A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (NCT06928376) | Chinese PLA General Hospital | 2024-04-18 |
| Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. (NCT06099418) | Nykode Therapeutics ASA | 2024-04-18 |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma (NCT06377566) | Memorial Sloan Kettering Cancer Center | 2024-04-17 |
| Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer (NCT06030622) | State University of New York - Downstate Medical Center | 2024-04-17 |
| A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies (NCT07011186) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-04-17 |
| Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome (NCT06256432) | Noorik Biopharmaceuticals AG | 2024-04-17 |
| Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) (NCT06287567) | Institute of Hematology & Blood Diseases Hospital, China | 2024-04-17 |
| High-Risk Metachronous Oligometastatic Prostate Cancer Trial (NCT06212583) | University of Maryland, Baltimore | 2024-04-17 |
| A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT06233864) | Sun Yat-sen University | 2024-04-17 |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs (NCT06228326) | Krystal Biotech, Inc. | 2024-04-17 |
| Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (NCT06178445) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2024-04-17 |
| Phase I-IIa, to Evaluate the Safety, Feasibility, and Efficacy of the Use of BIOCLEFT in the Treatment of Cleft Palate. (NCT06408337) | Elisa María Cubiles Montero de Espinosa | 2024-04-17 |
| Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer (NCT06387810) | Peking Union Medical College Hospital | 2024-04-17 |
| Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (NCT06123468) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2024-04-17 |
| A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery (NCT05316688) | University of Washington | 2024-04-17 |
| Efficacy of Inhaled Methoxyflurane (Penthrox) as Adjunct for Urologic Procedures Under Local Anesthetic: A Pilot Study (NCT07192198) | University of Manitoba | 2024-04-17 |
| A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer (NCT06162351) | Institut Curie | 2024-04-17 |
| NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC (NCT06405490) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-04-17 |
| A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) (NCT05576974) | University of Texas Southwestern Medical Center | 2024-04-17 |
| European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (NCT06137378) | University of Leipzig | 2024-04-17 |
| TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma (NCT06323525) | Chinese PLA General Hospital | 2024-04-17 |
| Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (NCT06325709) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-04-17 |
| MDMA for Co-occurring PTSD and OUD After Childbirth (NCT05219175) | University of New Mexico | 2024-04-16 |
| A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) (NCT06178055) | Kyoto Drug Discovery and Development Co., Ltd. | 2024-04-16 |
| Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer (NCT06207656) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2024-04-16 |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (NCT06043427) | Canadian Cancer Trials Group | 2024-04-16 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors (NCT05949632) | Incyte Corporation | 2024-04-16 |
| CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors (NCT06365671) | Ruijin Hospital | 2024-04-16 |
| First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer (NCT06253611) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2024-04-16 |
| PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC (NCT06375109) | Beijing Chest Hospital, Capital Medical University | 2024-04-16 |
| Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty (NCT06123715) | University Health Network, Toronto | 2024-04-16 |
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS (NCT06392126) | n-Lorem Foundation | 2024-04-16 |
| Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy (NCT06200155) | M.D. Anderson Cancer Center | 2024-04-16 |
| Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury (NCT05951777) | Hope Biosciences LLC | 2024-04-16 |
| Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer (NCT06254066) | Zhejiang Cancer Hospital | 2024-04-16 |
| A Study of MHB039A for Advanced Solid Tumor (NCT06345482) | Minghui Pharmaceutical (Hangzhou) Ltd | 2024-04-16 |
| ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer (NCT06397703) | NYU Langone Health | 2024-04-16 |
| Toripalimab Combined With SBRT for NSCLC (NCT06293690) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-04-15 |
| A Phase 2b/3 Study of TPX-115 on Partial-thickness Rotator Cuff Tear (NCT06414005) | Tego Science, Inc. | 2024-04-15 |
| LYell SYndrome MEsenchymal Stromal Cells Treatment (NCT04711200) | Assistance Publique - Hôpitaux de Paris | 2024-04-15 |
| JDQ443 for KRAS G12C NSCLC Brain Metastases (NCT05999357) | Maastricht University Medical Center | 2024-04-15 |
| KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors (NCT05906524) | Shanghai Kanda Biotechnology Co., Ltd. | 2024-04-15 |
| Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer (NCT06353061) | Peking Union Medical College Hospital | 2024-04-15 |
| Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (NCT06037811) | Tom Appleton | 2024-04-15 |
| Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations (NCT06299371) | Liaoning Cancer Hospital & Institute | 2024-04-15 |
| Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL (NCT06333509) | CARsgen Therapeutics Co., Ltd. | 2024-04-15 |
| Fecal Microbiota Transplantation for IBS (NCT05776914) | Madhusudan (Madhu) Grover, MBBS | 2024-04-15 |
| The SUGAR Study; SBRT and Relugolix) for Prostate Cancer (NCT06111781) | Yale University | 2024-04-15 |
| MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (NCT06227546) | Georgetown University | 2024-04-15 |
| Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure (NCT06319274) | Pär Johansson | 2024-04-15 |
| Platform Clinical Study for Conquering Scleroderma (NCT06195072) | Scleroderma Research Foundation, Inc. | 2024-04-15 |
| Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen (NCT06251947) | Shandong University | 2024-04-15 |
| Lumasiran in Hyperoxalaemic Patients on Haemodialysis (NCT06225544) | Charite University, Berlin, Germany | 2024-04-14 |
| A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma (NCT06485219) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2024-04-14 |
| Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma (NCT06376721) | Beijing Tongren Hospital | 2024-04-14 |
| Study of TDM-180935 in Atopic Dermatitis Patients (NCT06363461) | Technoderma Medicines Inc. | 2024-04-13 |
| A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy (NCT06169046) | Gianni Soraru | 2024-04-13 |